Endocannabinoid regulation of amyloid-induced neuroinflammation

Neurobiology of Aging

Volumn 36, Issue 11, 2015, Pages 3008-3019

  Vázquez, Carmen ^a   Tolón, Rosa M ^a   Grande, M Teresa ^b   Caraza, Marina ^a,b   Moreno, Marta ^a   Koester, Erin C ^c   Villaescusa, Borja ^a   Ruiz Valdepeñas, Lourdes ^a   Fernández Sánchez, Francisco Javier ^a   Cravatt, Benjamin F ^d   Hillard, Cecilia J ^c   Romero, Julián ^a,b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amyloid; Endocannabinoid; Glia; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANANDAMIDE; CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE; AMIDASE; AMYLOID; AUTACOID; CANNABINOID RECEPTOR; ENDOCANNABINOID; FATTY-ACID AMIDE HYDROLASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; GENE INACTIVATION; GLIOSIS; HUMAN; IN VIVO STUDY; MEMORY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENILE PLAQUE; SPATIAL MEMORY; AMYLOID PLAQUE; ANIMAL; C57BL MOUSE; DISEASE MODEL; FEMALE; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROGENIC INFLAMMATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMIDOHYDROLASES; AMYLOID; ANIMALS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; GLIOSIS; INFLAMMATION MEDIATORS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEUROGENIC INFLAMMATION; PLAQUE, AMYLOID; RECEPTORS, CANNABINOID; SPATIAL MEMORY;

EID: 84947041175     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.08.003     Document Type: Article

References (62)

1. Aso E., Juvés S., Maldonado R., Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis. 2013, 35:847-858.
2. Aso E., Palomer E., Juvés S., Maldonado R., Muñoz F.J., Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. J. Alzheimers Dis. 2012, 30:439-459.
3. Ativie F., Albayram O., Bach K., Pradier B., Zimmer A., Bilkei-Gorzo A. Enhanced microglial activity in FAAH-/- animals. Life Sci 2014, 10.1016/j.lfs.2014.12.016.
4. Bari M., Battista N., Fezza F., Finazzi-Agró A., Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J. Biol. Chem. 2005, 280:12212-12220.
5. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 2003, 23:11136-11141.
6. 1 or CB[U+2082] receptors. Br. J. Pharmacol. 2012, 166:1474-1489.
7. Cameron B., Landreth G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 2010, 37:503-509.
8. Chen R., Zhang J., Fan N., Teng Z., Wu Y., Yang H., Tang Y.P., Sun H., Song Y., Chen C. Delta-9-THC caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 2013, 155:1154-1165.
9. Chen R., Zhang J., Wu Y., Wang D., Feng G., Tang Y.P., Teng Z., Chen C. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2012, 2:1329-1339.
10. Clement A.B., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 2003, 23:3916-3923.
11. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad USA 2001, 98:9371-9376.
12. De Chiara V., Motta C., Rossi S., Suder V., Barbieri F., Lauro D., Bernardi G., Centonze D. Interleukin-1b alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. Neuroscience 2013, 250:232-239.
13. Del Rey A., Balschun D., Wetzel W., Randolf A., Besedovsky H.O. A cytokine network involving brain-borne IL1b, IL1-ra, IL-18, IL-6, and TNFa operates during long-term potentiation and learning. Brain Behav. Immun. 2013, 33:15-23.
14. Fowler C.J., Rojo M.L., Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?. Exp. Neurol. 2010, 224:37-47.
15. Gowran A., Noonan J., Campbell V.A. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci. Ther. 2011, 17:637-644.
16. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci. Ther. 2009, 15:65-75.
17. Jawhar S., Trawicka A., Jenneckens C., Bayer T.A., Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33:196.e29-196.e40.
18. Jung K.M., Astarita G., Yasar S., Vasilevko V., Cribbs D.H., Head E., Cotman C.W., Piomelli D. An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol. Aging 2012, 33:1522-1532.
19. Kerr D.M., Burke N.N., Ford G.K., Connor T.J., Harhen B., Egan L.J., Finn D.P., Roche M. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 204:53-63.
20. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., Jakobsson P.J., Marnett L.J. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem. 2002, 22:44877-44885.
21. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 2006, 46:101-122.
22. Marchalant Y., Cerbai F., Brothers H.M., Wenk G.L. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol. Aging 2008, 29:1894-1901.
23. Marchalant Y., Rosi S., Wenk G.L. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 2007, 144:1516-1522.
24. Martín-Moreno A.M., Brera B., Spuch C., Carro E., García-García L., Delgado M., Pozo M.A., Innamorato N.G., Cuadrado A., de Ceballos M.L. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 2012, 9:8.
25. Martín-Moreno A.M., Reigada D., Ramírez B.G., Mechoulam R., Innamorato N., Cuadrado A., de Ceballos M.L. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 2011, 79:964-973.
26. Martínez-Orgado J., Fernández-López D., Lizasoain I., Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Pat. CNS Drug Discov. 2007, 2:131-139.
27. Matousek S.B., Ghosh S., Shaftel S.S., Kyrkanides S., Olschowka J.A., O'Banion M.K. Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J. Neuroimmune Pharmacol. 2012, 7:156-164.
28. Matousek S.B., Hein A.M., Shaftel S.S., Olschowka J.A., Kyrkanides S., O'Banion M.K. Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J. Neurochem. 2010, 114:247-258.
29. Matsumura A., Suzuki S., Iwahara N., Hisahara S., Kawamata J., Suzuki H., Yamauchi A., Takata K., Kitamura Y., Shimohama S. Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. J. Alzheimers Dis. 2015, 44:409-423.
30. Mazzola C., Medalie J., Scherma M., Panlilio L.V., Solinas M., Tanda G., Drago F., Cadet J.L., Goldberg S.R., Yasar S. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem. 2009, 16:332-337.
31. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav Rev. 2009, 33:355-366.
32. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 1998, 433:139-142.
33. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 2003, 23:6470-6474.
34. Moreira F.A., Kaiser N., Monory K., Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
35. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005, 26:349-354.
36. Mukhopadhyay P., Horváth B., Rajesh M., Matsumoto S., Saito K., Bátkai S., Patel V., Tanchian G., Gao R.Y., Cravatt B.F., Haskó G., Pacher P. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic. Biol. Med. 2011, 50:179-195.
37. Mulder J., Zilberter M., Pasquaré S.J., Alpár A., Schulte G., Ferreira S.G., Köfalvi A., Martín-Moreno A.M., Keimpema E., Tanila H., Watanabe M., Mackie K., Hortobágyi T., de Ceballos M.L., Harkany T. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011, 134:1041-1060.
38. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
39. Ortega-Gutiérrez S., Molina-Holgado E., Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005, 52:163-168.
40. Panlilio L.V., Justinova Z., Goldberg S.R. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol. Ther. 2013, 138:84-102.
41. Patel S., Roelke C.T., Rademacher D.J., Hillard C.J. Inhibition of restraint stress-induced neural and behavioral activation by endogenous cannabinoid signaling. Eur. J. Neurosci. 2005, 21:1057-1069.
42. Piro J.R., Benjamin D.I., Duerr J.M., Pi Y., Gonzales C., Wood K.M., Schwartz J.W., Nomura D.K., Samad T.A. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012, 1:617-623.
43. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Eng. J. Med. 2010, 362:329-344.
44. Rogers J.T., Morganti J.M., Bachstetter A.D., Hudson C.E., Peters M.M., Grimmig B.A., Weeber E.J., Bickford P.C., Gemma C. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J. Neurosci. 2011, 31:16241-16250.
45. Rajesh M., Bátkai S., Kechrid M., Mukhopadhyay P., Lee W.S., Horváth B., Holovac E., Cinar R., Liaudet L., Mackie K., Haskó G., Pacher P. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012, 61:716-727.
46. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 23:1904-1913.
47. Ramos A. Animal models of anxiety: do I need multiple tests?. Trends Pharmacol. Sci. 2008, 29:493-498.
48. Rossi S., De Chiara V., Musella A., Sacchetti L., Cantarella C., Castelli M., Cavasinni F., Motta C., Studer V., Bernardi G., Cravatt B.F., Maccarrone M., Usiello A., Centonze D. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol. Pharmacol. 2010, 78:260-268.
49. Rossi S., Sacchetti L., Napolitano F., De Chiara V., Motta C., Studer V., Musella A., Barbieri F., Bari M., Bernardi G., Maccarrone M., Usiello A., Centonze D. Interleukin-1β causes anxiety by interacting with the endocannabinoid system. J. Neurosci. 2012, 32:13896-13905.
50. Scuderi C., Esposito G., Blasio A., Valenza M., Arietti P., Steardo L., Carnuccio R., De Filippis D., Petrosino S., Iuvone T., Di Marzo V., Steardo L. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J. Cell Mol. Med. 2011, 15:2664-2674.
51. Shaftel S.S., Griffin W.S., O'Banion M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflammation 2008, 5:7.
52. Shaftel S.S., Kyrkanides S., Olschowka J.A., Miller J.N., Johnson R.E., O'Banion M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 2007, 117:1595-1604.
53. Singh-Tahim A., Sántha P., Nagy I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 2005, 136:539-548.
54. Taylor D.R., Hooper N.M. Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin. Cell Dev. Biol. 2007, 18:638-648.
55. Trullas R., Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 1993, 111:323-331.
56. Varvel S.A., Cravatt B.F., Engram A.E., Lichtman A.H. Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J. Pharmacol. Exp. Ther. 2006, 317:251-257.
57. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007, 32:1032-1041.
58. Vázquez C., Tolón R.M., Pazos M.R., Moreno M., Koester E.C., Cravatt B.F., Hillard C.J., Romero J. Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: in vivo studies. Neurobiol. Dis. 2015, 79:41-50.
59. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
60. Weber A., Ni J., Ling K.H., Acheampong A., Tang-Liu D.D., Burk R., Cravatt B.F., Woodward D. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J. Lipid Res. 2004, 45:757-763.
61. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
62. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2:a006346.